Back to Hematology
Hematologyv2020Evidence-Based

International Prognostic Score for Asymptomatic Early-stage CLL (IPS-E)

Assesses prognosis of asymptomatic early-stage chronic lymphocytic leukemia (CLL) to predict time to first treatment (TTFT). The IPS-E was developed using individual patient data from 11 international cohorts (n=4933) and uses three independent prognostic factors to stratify patients into low, intermediate, and high-risk categories. This scoring system specifically addresses the clinical need for prognostic stratification in early-stage asymptomatic CLL patients who do not require immediate treatment according to iwCLL criteria. The IPS-E demonstrates excellent discrimination with C-index values of 0.74 in training and 0.70 in validation cohorts, making it a valuable tool for clinical management and early intervention clinical trial design. It enables clinicians to identify patients who may benefit from closer monitoring or consideration for clinical trials.

Clinical Input Parameters

×10⁹/L
Clinical Assessment
Awaiting Parameters
ips e score
—points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The International Prognostic Score for Asymptomatic Early-stage CLL (IPS-E) is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within hematology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

IPS-E Score = Unmutated IGHV (1) + Lymphocyte count >15×10⁹/L (1) + Palpable lymph nodes (1). Score ranges 0-3: Low risk (0), Intermediate risk (1), High risk (2-3)

Clinical Pearls & Practice Notes

  • The IPS-E was developed specifically for asymptomatic early-stage CLL patients (Binet A, Rai 0-I)
  • Based on analysis of 4,933 patients from 11 international cohorts
  • Three independent prognostic factors with equal weighting (1 point each)
  • Unmutated IGHV defined as <98% homology to germline sequences
  • Lymphocyte count >15×10⁹/L represents higher tumor burden at diagnosis
  • Palpable lymph nodes indicate more advanced disease within early stages
  • Primary endpoint is time to first treatment (TTFT) according to iwCLL criteria
  • C-index: 0.74 in training cohort, 0.70 in validation cohorts
  • Low-risk patients (score 0) have <0.1% 1-year and 8.4% 5-year treatment risk
  • Intermediate-risk patients (score 1) have 3.1% 1-year and 28.4% 5-year treatment risk
  • High-risk patients (score 2-3) have 61.2% 5-year treatment risk
  • Complements but does not replace the CLL-IPI for comprehensive prognostication
  • Useful for clinical trial stratification and early intervention study design
  • Should be applied only to patients meeting iwCLL watch-and-wait criteria
  • Regular monitoring intervals should be adjusted based on risk category
  • High-risk patients warrant consideration for early intervention trials
  • The score helps optimize surveillance schedules and patient counseling
  • Validated across multiple geographic regions and treatment eras

Evidence & Literature Citations

  1. Condoluci A, Terzi di Bergamo L, Langerbeins P, Hoechstetter MA, Herling CD, De Paoli L, et al. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood. 2020 May 21;135(21):1859-1869. doi: 10.1182/blood.2019003453.
  2. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018 Jun 21;131(25):2745-2760. doi: 10.1182/blood-2017-09-806398.
  3. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975 Aug;46(2):219-34. doi: 10.1182/blood.V46.2.219.219.

Score Interpretation Ranges

Low Risk0 – 0 pts

Score 0 points

Intermediate Risk1 – 1 pts

Score 1 point

High Risk2 – 3 pts

Score 2-3 points

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.